Találati lista | Tudóstér

001-es BibID:	BIBFORM083545
035-os BibID:	(WOS)000537433000017 (Scopus)85084167516
Első szerző:	Betteridge, Zoe
Cím:	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis / Zoe Betteridge, Hector Chinoy, Jiri Vencovsky, John Winer, Kiran Putchakayala, Pauline Ho, Ingrid Lundberg, Katalin Danko, Robert Cooper, Neil McHugh
Dátum:	2020
ISSN:	1462-0324 1462-0332
Megjegyzések:	OBJECTIVES: To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. METHODS: Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus erythematosus (200), Sjogren's syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as disease or healthy controls. RESULTS: IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients. Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment. CONCLUSION: We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good prognosis and a favourable response to treatment.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk autoantibodies autoantigens myositis
Megjelenés:	Rheumatology. - 59 : 5 (2020), p. 1026-1030. -
További szerzők:	Chinoy, Hector Vencovsky, Jiri Winer, John Putchakayala, Kiran Ho, Pauline Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Cooper, Robert G. McHugh, Neil
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM073045
Első szerző:	Ibrahim, Fowzia
Cím:	Second-line agents in myositis : 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids / Fowzia Ibrahim, Ernest Choy, Patrick Gordon, Caroline J. Doré, Alan Hakim, George Kitas, David Isenberg, Bridget Griffiths, Bryan Lecky, Kuntal Chakravarty, John Winer, Katalin Danko, Robert G. Cooper, Beverley White-Alao, David L. Scott
Dátum:	2015
ISSN:	1462-0324
Megjegyzések:	OBJECTIVE:Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.METHODS:A 56-week multicentre factorial-design double-blind placebo-controlled RCT compared steroids alone, MTX (15-25 mg weekly) plus steroids, ciclosporin (1-5 mg/kg/day) plus steroids and all three treatments. It enrolled adults with myositis (by Bohan and Peter criteria) with active disease receiving corticosteroids.RESULTS:A total of 359 patients were screened and 58 randomized. Of the latter, 37 patients completed 12 months of treatment, 7 were lost to follow-up and 14 discontinued treatment. Patients completing 12 months of treatment showed significant improvement (P < 0.001 on paired t-tests) in manual muscle testing (14% change), walking time (22% change) and function (9% change). Intention to treat and completer analyses indicated that ciclosporin monotherapy, MTX monotherapy and ciclosporin/MTX combination therapy showed no significant treatment effects in comparison with placebo.CONCLUSION:Neither MTX nor ciclosporin (by themselves or in combination) improved clinical features in myositis patients who had incompletely responded to glucocorticoids.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Rheumatology 54 : 6 (2015), p. 1050-1055. -
További szerzők:	Choy, Ernest Gordon, Patrick Doré, Caroline J. Hakim, Alan Kitas, George Isenberg, David A. Griffiths, Bridget Lecky, Bryan Chakravarty, Kuntal Winer, John Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Cooper, Robert G. White-Alao, Beverley Scott, David L.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: